CeciliaBlairLevandowskiMDPhD(She/Her)

Oncology • Chapel Hill, NC

Hematology/Oncology Fellow

Join to view full profile

Dr. Levandowski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Levandowski's full profile

Already have an account?

Office
UNC Hospitals
101 Manning Dr
Chapel Hill, NC 27514

Summary

eRNA production and p53 activity

The Δ40p53 isoform inhibits p53-dependent eRNA transcription and enables regulat

Using an innovative approach, this study reveal delat40p53 isoform tempers WTp53 activity by blocking p53 eRNA production to allow input from other TFs.

Education & Training

University of North Carolina HospitalsResidency, Internal Medicine, 2022 - 2024
University of Colorado School of Medicine Anschutz Medical CampusClass of 2022, MD
University of Colorado BoulderPhD, Biochemistry, 2014 - 2020
Davidson CollegeBS, Biology, 2004 - 2008

Certifications & Licensure

NC State Medical License 2022 - 2025

Publications & Presentations

PubMed

2 citations
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.
Daniel P Nussbaum, Colin A Martz, Andrew M Waters, Alejandro Barrera, Annie Liu
NPJ Precision Oncology. 2024-05-31
2 citations
Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers.
Kris Wood, Daniel Nussbaum, Colin Martz, Andrew Waters, Alejandro Barrera
Research Square. 2023-11-02
5 citations
Suppression of p53 response by targeting p53-Mediator binding with a stapled peptide.
Benjamin L Allen, Kim Quach, Taylor Jones, Cecilia B Levandowski, Christopher C Ebmeier
Cell Reports. 2022-04-05

Journal Articles

Suppression of p53 response by targeting p53–Mediator binding with a stapled peptide.
Allen, B.L., Quach, K., Levandowski, C.B., Jones, T., Ebmeier, C.C., Rubin, J.D., Read, T., Dowell, R.D., Schepartz, A., Taatjes, D.J., Cell Reports